Menopause Care Is Booming. Medicine Still Has to Come First.

A recent JAMA article on the expanding menopause marketplace deserves attention—not because it proves that hormone therapy, telehealth, supplements, or individualized menopause care are illegitimate, but because it asks an increasingly necessary question:

When does long-overdue medical attention become another wellness industry?

Women have been underserved in menopause care for decades. Many were told that hot flashes, disrupted sleep, mood changes, sexual symptoms, cognitive complaints, and changes in body composition were simply things they had to endure. Others were denied hormone therapy because clinicians continued to apply an overly broad interpretation of the original Women’s Health Initiative findings long after the evidence became more nuanced.

The renewed attention is therefore not the problem. Women deserve informed treatment options and clinicians who understand menopause.

The problem begins when unmet need becomes a sales opportunity.

HormoneSynergy Is Part of This Landscape

HormoneSynergy provides hormone therapy. We sometimes use compounded medications. We prescribe testosterone to selected women. We recommend supplements. We use advanced diagnostic testing. We provide private-pay Preventive Longevity Medicine.

Those similarities should be acknowledged plainly. A clinic does not become fundamentally different from the menopause marketplace simply by describing itself as personalized, integrative, evidence-based, or physician-led. Nearly every commercial clinic now uses some version of those words.

The difference must be demonstrated in the clinical process.

It appears in what a clinic does not promise, what it does not prescribe, what it does not test, and what it is willing to tell a patient she does not need.

Menopause Is Not a Universal Hormone Deficiency

Hormone therapy can be highly effective for vasomotor symptoms, genitourinary symptoms, sleep disruption related to hot flashes, and prevention of bone loss in appropriately selected women. For many patients, it can substantially improve quality of life.

That does not mean every woman must use hormone therapy.

It also does not mean estrogen should be marketed as a universal longevity drug that guarantees protection from cardiovascular disease, dementia, weight gain, or biological aging. Hormones may influence several of these systems, but influence is not the same as a guaranteed clinical outcome.

At HormoneSynergy, hormone therapy is one possible component of care. It is not the organizing principle around which every woman’s health must revolve.

A woman’s broader health may also involve:

• Cardiovascular and metabolic risk
• Bone density and fracture prevention
• Lean muscle mass and strength
• Sleep quality and sleep disorders
• Cognitive symptoms and neurological risk
• Nutrition, protein intake, and physical activity
• Medication effects and competing medical explanations
• Sexual health, pelvic health, and relationship context

Hormones can matter without being responsible for everything.

Personalized Care Is Not a Standardized Protocol

The JAMA article appropriately criticizes the idea that one menopause protocol fits everyone.

A branded protocol may still be standardized medicine dressed in personalized language: estrogen for nearly everyone, progesterone whether clearly indicated or not, testosterone for energy and muscle, thyroid medication based on broad symptom lists, several supplements, and repeated laboratory testing intended to move every marker toward a proprietary “optimal” range.

Actual individualized care is less tidy.

Two women of the same age with similar symptoms may receive different recommendations because their health histories, anatomy, family risks, treatment goals, medication use, cardiovascular profiles, bone health, and tolerance for uncertainty are different.

Sometimes individualized care means prescribing a treatment. Sometimes it means modifying the dose, changing the route, trying a nonhormonal option, addressing sleep or insulin resistance, or deciding that no additional treatment is warranted.

Testing Should Clarify Health, Not Create Deficiency

The article also questions the use of extensive hormone testing to chase idealized hormone targets.

That criticism is fair.

Hormone levels can sometimes be clinically useful, particularly when evaluating unusual symptoms, medication absorption, treatment safety, androgen exposure, thyroid function, or competing diagnoses. They should not, however, be treated as a mathematical scorecard proving that every woman must reach the same estrogen, progesterone, or testosterone number.

Symptoms, medical history, treatment response, side effects, and risk factors remain essential.

HormoneSynergy also uses diagnostics that extend beyond reproductive hormones. Depending on the patient, that may include cardiovascular biomarkers, body composition, bone density, glucose regulation, cognitive screening, vascular imaging, and other assessments relevant to aging and long-term health.

The purpose is not to find more things to treat. It is to understand which risks are meaningful enough to justify action.

Our Optimal Aging Assessment was designed around this broader clinical context rather than a hormone-only model.

Compounded Hormones Are Tools, Not Superior Hormones

FDA-approved hormone products are generally preferred when an appropriate formulation and dose are commercially available. They have standardized manufacturing requirements, established labeling, and regulatory review that compounded medications do not share in the same way.

Compounded hormones may still have a legitimate role when a patient requires a dose, delivery system, ingredient profile, or formulation that is not commercially available.

What they should not be called is automatically safer, more natural, more bioidentical, or more personalized.

A medication does not become superior simply because it was compounded. The clinical reason for using it should be specific and defensible.

Testosterone Requires More Honesty, Not Less Access

Testosterone therapy for women is one of the most contested areas discussed in the article.

The strongest evidence supports carefully dosed testosterone for appropriately diagnosed hypoactive sexual desire disorder in postmenopausal women. Evidence for broader claims involving energy, cognition, mood, muscle mass, and general optimization is less established.

That does not require pretending that patients and clinicians never observe benefits outside a narrowly defined endpoint. It does require distinguishing among:

• Established evidence
• Emerging evidence
• Clinical observation
• Patient preference
• Marketing claims

Those categories are not interchangeable.

When testosterone is considered, patients should understand the evidence, limitations, dosing strategy, monitoring plan, and possible androgenic effects. More access without informed consent is not progress. Neither is refusing to discuss the therapy because the evidence is incomplete.

Supplements Should Have a Job

The menopause supplement market is crowded with products claiming to improve hot flashes, sleep, hair growth, metabolism, libido, cognition, cortisol, inflammation, and hormone balance—often at the same time.

Some supplements have useful evidence for specific purposes. Many have weak, indirect, or nonexistent evidence. Product quality also varies considerably.

HormoneSynergy recommends and sells nutritional supplements, including our RetzlerRx® formulations. That creates a responsibility to be transparent about what a supplement can reasonably accomplish and where the evidence ends.

A supplement should have a defined clinical purpose. It should not be continued indefinitely simply because it was included in a protocol. It should not replace an effective medication, resistance training, adequate protein, sleep treatment, or appropriate diagnostic evaluation.

When it does not provide meaningful value, the appropriate recommendation may be to stop taking it.

Medicine Is More Than Access

Telehealth has helped women reach clinicians with menopause expertise, particularly in areas where local care is limited. That is a meaningful improvement.

Convenient access, however, is not the same as comprehensive care.

A short online intake followed by a prescription may be efficient, but it cannot always integrate cardiovascular risk, bone health, cognition, body composition, family history, medication interactions, pelvic symptoms, sleep, and long-term follow-up.

The point is not that every patient needs exhaustive testing or an extensive longevity program. Most do not.

The point is that menopause symptoms occur inside a whole person. Good medicine must be capable of seeing more than the symptom that generated the prescription.

The Most Important Difference Is Restraint

The menopause marketplace often presents more treatment as better care.

More hormones. More supplements. More laboratory panels. More optimization. More monthly products. More fear about what will happen if a woman does not begin immediately.

Preventive medicine should not be passive, but it should be proportionate.

At HormoneSynergy, our goal is not to convince every woman that she is hormonally deficient, biologically unfinished, or one protocol away from perfect aging. We use hormones, medications, diagnostics, lifestyle strategies, and supplements selectively—when the expected benefit is credible, the risks are understood, and the intervention serves the patient rather than the marketplace.

Menopause care needed greater attention. It still does.

It also needs clinical judgment, intellectual honesty, and clinicians who remain willing to say that sometimes the most personalized recommendation is not to add another treatment.

Frequently Asked Questions

Does HormoneSynergy believe every woman should use hormone therapy?

No. Hormone therapy can be highly effective for appropriately selected women, particularly for menopausal symptoms and prevention of bone loss. Whether it is appropriate depends on the patient’s symptoms, health history, risks, preferences, and treatment goals.

Does HormoneSynergy use compounded hormones?

Yes, when there is a legitimate clinical reason that an FDA-approved product does not adequately address, such as a required dose, formulation, delivery system, or excipient consideration. Compounded medication is not automatically safer or more personalized.

Does HormoneSynergy prescribe testosterone to women?

Testosterone may be considered for selected women following an individualized evaluation, informed consent, appropriate dosing, and monitoring. The strongest evidence relates to hypoactive sexual desire disorder. Evidence for other potential benefits is still developing.

Are supplements part of HormoneSynergy care?

They may be, but supplements are considered adjuncts rather than substitutes for medical treatment, nutrition, resistance training, sleep care, or appropriate diagnostics. Recommendations should have a defined purpose and should be reassessed over time.

How is the Optimal Aging Assessment different from a menopause hormone panel?

The Optimal Aging Assessment evaluates broader areas of health that may include cardiovascular risk, bone density, body composition, cognition, metabolic health, medical history, and other factors relevant to aging. It is not designed simply to identify hormone deficiencies or move every laboratory value toward a predetermined target.

Explore more evidence-based articles in the HormoneSynergy Preventive Longevity Medicine Resource Library.